Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 11559 for:    Anti-Infective Agents AND antibacterial

Nurse Promotion of IV to PO Antimicrobial Conversion (FERN-IPO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03761043
Recruitment Status : Recruiting
First Posted : December 3, 2018
Last Update Posted : February 27, 2019
Sponsor:
Information provided by (Responsible Party):
Sean Gorman, Kelowna General Hospital

Brief Summary:
This is a prospective, quasi-experimental, historically controlled study to evaluate if a behavioural change intervention informed by the COM-B model of behaviour change can improve nurses' self-perceived capability, opportunity, and motivation to engage in the assessment of patients who may be appropriate for IV to PO antimicrobial conversion. This study also seeks to determine if this translates into an increase in IV to PO antimicrobial conversion rates in the acute care setting.

Condition or disease Intervention/treatment Phase
Behavior Change Bacterial Infections Behavioral: Professional Behavior Change Intervention Not Applicable

Detailed Description:
Current antimicrobial stewardship guidelines recommend appropriate and timely IV to PO antimicrobial conversion in hospitalized patients. Published rates of IV to PO antimicrobial conversion are consistently below 50% in eligible inpatients. Studies have suggested that nurses may be well positioned to provide a positive influence on prescriber behavior related to antimicrobial IV to PO conversion, however, no published research has evaluated the impact of nurses on antimicrobial IV to PO conversion rates. Published research has described the barriers and enablers to nurse participation in promoting antimicrobial IV to PO conversion using the COM-B model of behaviour change. This quasi-experimental study will evaluate whether determinants of nurse behaviour and their actual behaviour can be changed to increase antimicrobial IV to PO conversion rates in hospitalized patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 276 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Fostering Engagement From Nurses in Promoting IV to PO Antimicrobial Conversion: The FERN-IPO Study
Actual Study Start Date : January 8, 2019
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics

Arm Intervention/treatment
No Intervention: Pre-Intervention Arm
The nurses will have not been exposed to the behavior change intervention.
Experimental: Post-Intervention Arm
The nurses will have been exposed to the behavior change intervention.
Behavioral: Professional Behavior Change Intervention
IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
Other Names:
  • Printed educational materials
  • Educational meetings
  • Educational outreach visits
  • Local opinion leaders
  • Reminders




Primary Outcome Measures :
  1. IV to PO antimicrobial conversion rate [ Time Frame: Six months (three months pre-intervention, three months post-intervention) ]
    Incidence of IV to PO antimicrobial conversion (defined as the initiation of a PO antimicrobial within 24 hours of discontinuation of an IV antimicrobial during a single treatment course in a specific patient) before and after behavior change intervention


Secondary Outcome Measures :
  1. Days of IV therapy prior to conversion to PO antimicrobial [ Time Frame: Six months (three months pre-intervention, three months post-intervention) ]
    For treatment courses that undergo IV to PO antimicrobial conversion, the days of IV antimicrobial therapy prior to PO conversion before and after intervention

  2. Nurse perceptions of capability, opportunity and motivation to promote IV to PO antimicrobial conversion [ Time Frame: Six months (three months pre-intervention, three months post-intervention) ]
    Constructs are derived using the Theoretical Domains Framework and assess nurse perceived capability, motivation, and opportunity to promote IV to PO antimicrobial conversion using a 7-point Likert scale (1 - Strongly Disagree, 2 - Disagree, 3- Slightly Disagree, 4 - Neither Agree or Disagree, 5 - Slightly Agree, 6 - Agree, 7- Strongly Agree). The average Likert scale score for each of nine constructs (based on the Theoretical Domains Framework) will be calculated for the pre-intervention period and the post-intervention period. Change in the average Likert score for each construct (question) in the pre-intervention period versus the post-intervention period will be compared for each construct. A higher average Likert score on a construct in the post-intervention period compared to the pre-intervention period indicates improved perceptions about capability, opportunity, or motivation to promote IV to PO antimicrobial conversion.


Other Outcome Measures:
  1. Balancing measure - Failed IV to PO antimicrobial conversion [ Time Frame: Six months (three months pre-intervention, three months post-intervention ]
    Incidence of failed IV to PO antimicrobial conversion (defined as the re-initiation of an IV antimicrobial within seven days following IV to PO conversion of an antimicrobial during a single treatment course for a specific patient) pre and post-intervention

  2. Subgroup Analysis 1: Nursing Unit Conversion Comparison [ Time Frame: Six months (three months pre-intervention, three months post-intervention) ]
    Incidence of IV to PO antimicrobial conversion on nursing unit 1 (contains a clinical pharmacist) versus nursing unit 2 (does not contain a clinical pharmacist) pre and post-intervention

  3. Subgroup Analysis 2: High Bioavailability Antimicrobial Conversion [ Time Frame: Six months (three months pre-intervention, three months post-intervention) ]
    Incidence of IV to PO antimicrobial conversion for highly bioavailable (F ≥ 80%) antimicrobials pre and post-intervention

  4. Subgroup Analysis 2: Non-High Bioavailability Antimicrobial Conversion [ Time Frame: Six months (three months pre-intervention, three months post-intervention) ]
    Incidence of IV to PO antimicrobial conversion for non-highly bioavailable (F < 80%) antimicrobials pre and post-intervention



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Nineteen years of age or older
  • Employed as a RN or LPN at KGH in any capacity (full-time, part-time or casual employee)
  • Practicing on a medicine/thoracic surgery ward (4A) or medicine/oncology/respiratory ward (4B)

Exclusion Criteria:

  • RNs or LPNs on orientation shifts/training
  • RNs or LPNs not engaged in patient care
  • Student nurses/nurses in training

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03761043


Contacts
Layout table for location contacts
Contact: Sean Gorman, PharmD 2504697070 ext 12252 sean.gorman@interiorhealth.ca

Locations
Layout table for location information
Canada, British Columbia
Kelowna General Hospital Recruiting
Kelowna, British Columbia, Canada, V1Y1T2
Contact: Sean K Gorman, PharmD         
Sponsors and Collaborators
Kelowna General Hospital
Investigators
Layout table for investigator information
Principal Investigator: Victoria Cox, PharmD Interior Health Authority

Publications:
Layout table for additonal information
Responsible Party: Sean Gorman, Pharmacy Coordinator, Clinical Quality & Research, Kelowna General Hospital
ClinicalTrials.gov Identifier: NCT03761043     History of Changes
Other Study ID Numbers: IH1803202
First Posted: December 3, 2018    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sean Gorman, Kelowna General Hospital:
Nurse
Antibiotic step-down

Additional relevant MeSH terms:
Layout table for MeSH terms
Bacterial Infections
Anti-Infective Agents
Anti-Bacterial Agents